SOCC inhibitors targeting STIM1-Orai1 effectively prevent Ca2+ overload and ameliorate the decline in the contractile performance in myotubes from DMD-patient-derived induced pluripotent stem cells [68]. This evidence concerns the gene ORAI1 and Duchenne muscular dystrophy.